lyxiga
Lyxiga is a prescription medication used to treat rheumatoid arthritis (RA) and psoriatic arthritis (PsA). It is a selective inhibitor of Janus kinase (JAK) 1, which is a protein involved in the inflammatory response. By inhibiting JAK1, Lyxiga helps to reduce inflammation and improve symptoms in patients with RA and PsA.
Lyxiga is available in tablet form and is typically taken once daily. It is usually prescribed in
Lyxiga was approved by the U.S. Food and Drug Administration (FDA) in 2016 and is marketed under